Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.
The Company expects to hold an End-of-Phase 2 meeting with the US FDA in the second quarter of 2020 and anticipates starting Phase 3 later in 2020.
Chris Warburton shares the impact of severe breathlessness on his life."The best you can do is learn how to manage, but not control, your condition. It gradually squeezes the life out of you. Literally."
The first-in-class development candidate has "massive potential to impact lives of COPD and asthma patients."
Millions of patients remain symptomatic despite maximum treatment with available COPD therapies. They urgently need new treatments.
Our first-in-class candidate is effective on top of existing therapies in maximally treated patients with no further treatment options.
Robert Wise, MD, Professor of Medicine at John Hopkins University, explains the urgent need for a COPD therapy with a new mode of action.
Kathleen Rickard, CMO, explains ensifentrine's clinical progress and plans to enter Phase 3 in 2020.
John Linnell, COPD patient and advocate for the COPD Foundation talks about the difficulty of living with this serious unmet need.
If a jumbo jet crashed every day, that's the same number of people who die everyday from COPD.
Ensifentrine is a bi-functional molecule that works as a bronchodilator and an anti inflammatory in a single compound.
Ensifentrine acts as both a bronchodilator and an anti-inflammatory agent in one compound.